

**TREATMENTTRENDS®: GLAUCOMA (US) 2012**

*BioTrends Research Group is pleased to announce the continuation of **TreatmentTrends®: Glaucoma** in 2012. In this report, current trends in the management of glaucoma are examined from the perspective of glaucoma specialists and general ophthalmologists. TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.*

**SAMPLE FRAME AND METHODOLOGY**

74 glaucoma specialists and 26 general ophthalmologists complete a 45 minute online quantitative survey with several open ended questions for qualitative feedback

To qualify, respondents must meet the following criteria:

- Minimum of 50 primary glaucoma patients under management
- Have been in practice a minimum of 2 years and a maximum of 30 years
- More than 75% of professional time spent in clinical practice

**PRICE**

\$32,000

**RELATED 2012 REPORTS**

TreatmentTrends®: AMD  
TreatmentTrends®: Uveitis  
LaunchTrends®: Eylea

**PROJECT OBJECTIVES**

- Understand the relative glaucoma patient load by disease characteristics with a specific focus on primary open-angle glaucoma (POAG)
- Understand product attributes that are most important to ophthalmologists when selecting POAG therapy and compare the different brands on how they are perceived to perform against each attribute
- Understand how the use of each brand is expected to change in the next six months and what factors are driving those trends
- Evaluate sales and messaging efforts of POAG therapies
- Assess awareness of and interest in POAG therapies that are in late stage development

**DELIVERABLES**


- Final report in PowerPoint format
- Complete set of frequency tables, summary statistics, and cross tabulations
- Proprietary question slide deck and frequency tables
  - Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions

**REPORT DATES**

Date comments/proprietary questions are due	Field date	Publication date
February 3, 2012	February 16, 2012	March 22, 2012

**TABLE OF CONTENTS**

Introduction.....	4
Market Background	
Market News	
Methodology	
Research Objectives	
Executive Summary.....	14
Respondent Demographics.....	19
Respondent Demographics	
Practice Demographics	
Primary Conditions Treated	
Meeting Attendance Related to Glaucoma	
Current Medical Practice.....	24
Glaucoma Patient Volume and Share	
Glaucoma Patient Referrals	
Glaucoma Procedures Performed	
Improved Therapy Need Across Ophthalmology Indications	
Improved Therapy Need Across Glaucoma-Related Disorders	
Current Treatment of POAG.....	30
Recent Changes in Management / Treatment of POAG	
POAG Patient Share by Type	
POAG Treatment Approach	
Reasons for NOT Treating POAG Pharmacologically	
Current Drug Class Allocation for POAG	
Frequently Used Combination Treatments in POAG	
Monotherapy Versus Adjunctive Use of Drug Classes in POAG	
Alpha Agonist Product Allocation for POAG	
Beta Blocker Product Allocation for POAG	
Carbonic Anhydrase Inhibitor Product Allocation for POAG	
Parasympathomimetic Product Allocation for POAG	
Fixed Combination Product Allocation for POAG	
Prostaglandin Analog Product Allocation for POAG	
Most Likely Initiation of Brand by Patient Type	
Recent Change in Prescribing	
Reason for Recent Increase / Decrease in Prescribing	
Brand Discontinuations Within the First Year	
Overall Satisfaction with Primary Brands	
Overall Satisfaction with Other Brands	
Overall Satisfaction with Generic Agents	
Competitive Landscape.....	54
Brand Overall Performance	
Relative Brand Preference	
Attribute Importance and Brand Perception	
Stated versus Derived Importance of Attributes	



**TABLE OF CONTENTS CONTINUED**

Statement Agreement.....	65
Statement Agreement	
Current Areas of Controversy and / or Discussion Regarding POAG	
Impact of Patient Request for a Generic Switch	
Prior Status of Patients Receiving Generic latanoprost	
Promotional Activity.....	71
Detailing Frequency and Extent	
Aided Message Recall from Recent Detailing	
Satisfaction with Sales Representatives	
Perceived Impact of Detailing on Willingness to Prescribe	
Usefulness of Sources of Product Information	
Anticipated Future Treatment of POAG.....	86
POAG Treatment Approach	
Anticipated Drug Class Allocation for POAG	
Anticipated Alpha Agonist Product Allocation for POAG	
Anticipated Beta Blocker Product Allocation for POAG	
Anticipated Carbonic Anhydrase Inhibitor Product Allocation for POAG	
Anticipated Parasympathomimetic Product Allocation for POAG	
Anticipated Fixed Combination Product Allocation for POAG	
Anticipated Prostaglandin Analog Product Allocation for POAG	
Anticipated Lumigan Allocation for POAG	
Major Obstacles to Increased Prescribing by Brand	
Products in Development for POAG.....	98
Desired Attributes in New Glaucoma Treatments	
Other Unmet Needs Mentioned	
Unaided/Aided Awareness of Products in Development for POAG	
Aided Familiarity of Products in Development	
Interest in Products in Development	
Current Product Replacement by Products in Development	
Perception of Clinical Value of Products in Development	
Reason for Value in Products in Development	
Favorability and Uniqueness Ratings of Zioptan	
Perceived Advantages and Disadvantages of Zioptan	
Anticipated Start to Use Zioptan	
Willingness to Prescribe Zioptan and Likely Patient Share	
Appendix .....	104